🇺🇸 FDA
Pipeline program

donor lymphocyte infusion

MRD-directed DLI-2016

Phase 3 mab completed

Quick answer

donor lymphocyte infusion for Minimal Residual Disease is a Phase 3 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Minimal Residual Disease
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials